Direxion Daily S&P Biotech Bull 3X ETF
LABU
18 hedge funds and large institutions have $29.3M invested in Direxion Daily S&P Biotech Bull 3X ETF in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 2 closing their positions.
140% more capital invested
Capital invested by funds: $12.2M → $29.3M (+$17.1M)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
13% more funds holding
Funds holding: 16 → 18 (+2)
0.38% more ownership
Funds ownership: 0.22% → 0.61% (+0.38%)
22% less call options, than puts
Call options by funds: $24.1M | Put options by funds: $30.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$10.1M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.17M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$877K |
| 4 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
+$610K |
| 5 |
OPPM
Opus Point Partners Management
New York
|
+$367K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$3.92M |
| 2 |
Jane Street
New York
|
-$618K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$462K |
| 4 |
CT
CMT Trading
Chicago,
Illinois
|
-$350K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$158K |
LABU Hedge Fund Activity: Q2 2017 in Review
18 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bull 3X ETF (LABU) for Q2 2017, worth a combined $29.3M — up 140% from $12.2M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new LABU positions and 2 closed out — a net gain of 2 holders — while 8 added to existing stakes and 5 trimmed.
The largest buyer was Citigroup, opening a new position worth an estimated $10.1M. The largest seller was Virtu Financial, cutting an estimated $3.92M.
- 18 institutional investors held Direxion Daily S&P Biotech Bull 3X ETF (LABU) as of Q2 2017, up from 16 in Q1 2017.
- Funds reported $29.3M of Direxion Daily S&P Biotech Bull 3X ETF stock for Q2 2017, up 140% quarter-over-quarter.
- 4 funds opened new Direxion Daily S&P Biotech Bull 3X ETF positions in Q2 2017 and 2 closed out, a net change of +2 holders.
- The largest Direxion Daily S&P Biotech Bull 3X ETF buyer in Q2 2017 was Citigroup, an estimated $10.1M added.
- The largest Direxion Daily S&P Biotech Bull 3X ETF seller in Q2 2017 was Virtu Financial, an estimated $3.92M sold.
Based on aggregated 13F filings for Q2 2017.